Arterial hypertension in cancer: The elephant in the room

Giuseppina Novo, Matteo Sarocchi, Giacomo Tini, Eleonora Arboscello, Paolo Spallarossa, Giuliano Tocci, Giorgio Ghigliotti, Daniel Lenihan, Claudio Brunelli, Massimo Volpe

Risultato della ricerca: Article

Abstract

The great therapeutical success achieved by oncology is counterbalanced by growing evidences of cardiovascular (CV) toxicity due to many antineoplastic treatments. Cardiac adverse events may cause premature discontinuation of effective oncologic treatments or occur as late events undermining the oncologic success. Arterial hypertension is both the most common comorbidity in cancer patients and a frequent adverse effect of anticancer therapies. A pre-existing hypertension is known to increase the risk of other cardiac adverse events due to oncologic treatments, in particular heart failure. Moreover, as a strict association between cancer and CV diseases has emerged over the recent years, various analyses have shown a direct relationship between hypertension and cancer incidence and mortality. Finally, many antineoplastic treatments may cause a rise in blood pressure (BP) values, particularly the novel anti VEGF agents, this possibly compromising efficacy of chemotherapy. Aim of this review is to revise the topic and the many aspects linking arterial hypertension and cancer, and to provide a comprehensive and practical guide of the current treatment approaches.
Lingua originaleEnglish
pagine (da-a)133-139
Numero di pagine7
RivistaINTERNATIONAL JOURNAL OF CARDIOLOGY
Volume281
Stato di pubblicazionePublished - 2019

Fingerprint

Hypertension
Neoplasms
Antineoplastic Agents
Therapeutics
Prehypertension
Vascular Endothelial Growth Factor A
Comorbidity
Cardiovascular Diseases
Heart Failure
Blood Pressure
Drug Therapy
Mortality
Incidence

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cita questo

Novo, G., Sarocchi, M., Tini, G., Arboscello, E., Spallarossa, P., Tocci, G., ... Volpe, M. (2019). Arterial hypertension in cancer: The elephant in the room. INTERNATIONAL JOURNAL OF CARDIOLOGY, 281, 133-139.

Arterial hypertension in cancer: The elephant in the room. / Novo, Giuseppina; Sarocchi, Matteo; Tini, Giacomo; Arboscello, Eleonora; Spallarossa, Paolo; Tocci, Giuliano; Ghigliotti, Giorgio; Lenihan, Daniel; Brunelli, Claudio; Volpe, Massimo.

In: INTERNATIONAL JOURNAL OF CARDIOLOGY, Vol. 281, 2019, pag. 133-139.

Risultato della ricerca: Article

Novo, G, Sarocchi, M, Tini, G, Arboscello, E, Spallarossa, P, Tocci, G, Ghigliotti, G, Lenihan, D, Brunelli, C & Volpe, M 2019, 'Arterial hypertension in cancer: The elephant in the room', INTERNATIONAL JOURNAL OF CARDIOLOGY, vol. 281, pagg. 133-139.
Novo G, Sarocchi M, Tini G, Arboscello E, Spallarossa P, Tocci G e altri. Arterial hypertension in cancer: The elephant in the room. INTERNATIONAL JOURNAL OF CARDIOLOGY. 2019;281:133-139.
Novo, Giuseppina ; Sarocchi, Matteo ; Tini, Giacomo ; Arboscello, Eleonora ; Spallarossa, Paolo ; Tocci, Giuliano ; Ghigliotti, Giorgio ; Lenihan, Daniel ; Brunelli, Claudio ; Volpe, Massimo. / Arterial hypertension in cancer: The elephant in the room. In: INTERNATIONAL JOURNAL OF CARDIOLOGY. 2019 ; Vol. 281. pagg. 133-139.
@article{f4a0d0c779c2486ba7300e27a2b6a515,
title = "Arterial hypertension in cancer: The elephant in the room",
abstract = "The great therapeutical success achieved by oncology is counterbalanced by growing evidences of cardiovascular (CV) toxicity due to many antineoplastic treatments. Cardiac adverse events may cause premature discontinuation of effective oncologic treatments or occur as late events undermining the oncologic success. Arterial hypertension is both the most common comorbidity in cancer patients and a frequent adverse effect of anticancer therapies. A pre-existing hypertension is known to increase the risk of other cardiac adverse events due to oncologic treatments, in particular heart failure. Moreover, as a strict association between cancer and CV diseases has emerged over the recent years, various analyses have shown a direct relationship between hypertension and cancer incidence and mortality. Finally, many antineoplastic treatments may cause a rise in blood pressure (BP) values, particularly the novel anti VEGF agents, this possibly compromising efficacy of chemotherapy. Aim of this review is to revise the topic and the many aspects linking arterial hypertension and cancer, and to provide a comprehensive and practical guide of the current treatment approaches.",
keywords = "Anthracyclines, Anti VEGF agents, Anti-hypertensive therapy, Arterial hypertension, Cancer, Cardiology and Cardiovascular Medicine, Cardiotoxicity",
author = "Giuseppina Novo and Matteo Sarocchi and Giacomo Tini and Eleonora Arboscello and Paolo Spallarossa and Giuliano Tocci and Giorgio Ghigliotti and Daniel Lenihan and Claudio Brunelli and Massimo Volpe",
year = "2019",
language = "English",
volume = "281",
pages = "133--139",
journal = "INTERNATIONAL JOURNAL OF CARDIOLOGY",
issn = "0167-5273",

}

TY - JOUR

T1 - Arterial hypertension in cancer: The elephant in the room

AU - Novo, Giuseppina

AU - Sarocchi, Matteo

AU - Tini, Giacomo

AU - Arboscello, Eleonora

AU - Spallarossa, Paolo

AU - Tocci, Giuliano

AU - Ghigliotti, Giorgio

AU - Lenihan, Daniel

AU - Brunelli, Claudio

AU - Volpe, Massimo

PY - 2019

Y1 - 2019

N2 - The great therapeutical success achieved by oncology is counterbalanced by growing evidences of cardiovascular (CV) toxicity due to many antineoplastic treatments. Cardiac adverse events may cause premature discontinuation of effective oncologic treatments or occur as late events undermining the oncologic success. Arterial hypertension is both the most common comorbidity in cancer patients and a frequent adverse effect of anticancer therapies. A pre-existing hypertension is known to increase the risk of other cardiac adverse events due to oncologic treatments, in particular heart failure. Moreover, as a strict association between cancer and CV diseases has emerged over the recent years, various analyses have shown a direct relationship between hypertension and cancer incidence and mortality. Finally, many antineoplastic treatments may cause a rise in blood pressure (BP) values, particularly the novel anti VEGF agents, this possibly compromising efficacy of chemotherapy. Aim of this review is to revise the topic and the many aspects linking arterial hypertension and cancer, and to provide a comprehensive and practical guide of the current treatment approaches.

AB - The great therapeutical success achieved by oncology is counterbalanced by growing evidences of cardiovascular (CV) toxicity due to many antineoplastic treatments. Cardiac adverse events may cause premature discontinuation of effective oncologic treatments or occur as late events undermining the oncologic success. Arterial hypertension is both the most common comorbidity in cancer patients and a frequent adverse effect of anticancer therapies. A pre-existing hypertension is known to increase the risk of other cardiac adverse events due to oncologic treatments, in particular heart failure. Moreover, as a strict association between cancer and CV diseases has emerged over the recent years, various analyses have shown a direct relationship between hypertension and cancer incidence and mortality. Finally, many antineoplastic treatments may cause a rise in blood pressure (BP) values, particularly the novel anti VEGF agents, this possibly compromising efficacy of chemotherapy. Aim of this review is to revise the topic and the many aspects linking arterial hypertension and cancer, and to provide a comprehensive and practical guide of the current treatment approaches.

KW - Anthracyclines

KW - Anti VEGF agents

KW - Anti-hypertensive therapy

KW - Arterial hypertension

KW - Cancer

KW - Cardiology and Cardiovascular Medicine

KW - Cardiotoxicity

UR - http://hdl.handle.net/10447/354558

UR - http://www.elsevier.com/locate/ijcard

M3 - Article

VL - 281

SP - 133

EP - 139

JO - INTERNATIONAL JOURNAL OF CARDIOLOGY

JF - INTERNATIONAL JOURNAL OF CARDIOLOGY

SN - 0167-5273

ER -